Belite Bio Completes Enrollment in Key Stargardt Disease Clinical Trial, On Track for 1H 2026 NDA
Summary
Belite Bio announced the completion of enrollment for its Phase 2/3 DRAGON II clinical trial of tinlarebant for Stargardt Disease, keeping the company on schedule for a New Drug Application submission in the first half of 2026.
Key Events
-
DRAGON II Enrollment Completed
Belite Bio has completed enrollment of 60 adolescent subjects in its global Phase 2/3 DRAGON II clinical trial for tinlarebant, targeting Stargardt Disease (STGD1).
-
NDA Submission On Track
The company remains on schedule to submit a New Drug Application (NDA) for tinlarebant to the U.S. FDA in the first half of 2026.
-
Prior Efficacy Demonstrated
Tinlarebant previously met its primary endpoint in the pivotal global Phase 3 DRAGON trial, showing a 36% reduction in lesion growth.
Analysis
The completion of enrollment in the DRAGON II clinical trial for tinlarebant is a significant positive milestone for Belite Bio. Tinlarebant, which previously demonstrated clinical efficacy in a pivotal Phase 3 trial, is a lead candidate for Stargardt Disease, a condition with high unmet medical need. This development de-risks the clinical timeline and reinforces the company's commitment to its planned NDA submission in 1H 2026, potentially bringing a new treatment to market. The drug's multiple regulatory designations further underscore its potential importance.
At the time of this filing, BLTE was trading at $165.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $49.00 to $174.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.